2007 was a really good year for Novozymes. Growth was the theme of the year, with sales growth higher than expected at 14%. The financial results were satisfactory, particularly in the light of high energy and raw material prices. Unfavorable exchange rate movements had a negative impact on the results measured in DKK. Growth in earnings was 11%, and free cash flow was DKK 963 million. The high rate of sales growth is expected to continue in 2008 and onwards, and therefore it has been decided to expand the production in the USA. Download the full stock exchange announcement here
Recommended Reading
-
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...
Read More -
COPENHAGEN, Denmark – May 5, 2026. In the first quarter of 2026, Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.8%. Ester Baiget, President & CEO: ...
Read More